These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34424760)

  • 61. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
    Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
    Hosono H; Ohishi T; Takei J; Asano T; Sayama Y; Kawada M; Kaneko MK; Kato Y
    Oncol Lett; 2020 Dec; 20(6):383. PubMed ID: 33154781
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A defucosylated anti-PD-L1 monoclonal antibody 13-mG
    Takei J; Ohishi T; Kaneko MK; Harada H; Kawada M; Kato Y
    Biochem Biophys Rep; 2020 Dec; 24():100801. PubMed ID: 32923698
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anti‑EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas.
    Kaneko MK; Ohishi T; Takei J; Sano M; Nakamura T; Hosono H; Yanaka M; Asano T; Sayama Y; Harada H; Kawada M; Kato Y
    Oncol Rep; 2020 Dec; 44(6):2517-2526. PubMed ID: 33125138
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
    Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
    Kato Y; Ohishi T; Kawada M; Maekawa N; Konnai S; Itai S; Yamada S; Kaneko MK
    Biochem Biophys Rep; 2019 Mar; 17():23-26. PubMed ID: 30519645
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Masuda Y; Yamashita S; Nakayama Y; Shimizu R; Konishi M
    Biol Pharm Bull; 2024; 47(4):840-847. PubMed ID: 38616114
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
    Barok M; Tanner M; Köninki K; Isola J
    Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
    Albanell J; Codony J; Rovira A; Mellado B; Gascón P
    Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
    [TBL] [Abstract][Full Text] [Related]  

  • 72. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
    Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
    Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
    Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
    MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression.
    Masu T; Atsukawa M; Nakatsuka K; Shimizu M; Miura D; Arai T; Harimoto H; Kondo C; Kaneko K; Futagami S; Kawamoto C; Takahashi H; Iwakiri K
    PLoS One; 2018; 13(12):e0200664. PubMed ID: 30596643
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG
    Asano T; Tanaka T; Suzuki H; Li G; Ohishi T; Kawada M; Yoshikawa T; Kaneko MK; Kato Y
    Antibodies (Basel); 2022 Nov; 11(4):. PubMed ID: 36546899
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
    Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
    Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
    Singh R; Kim WJ; Kim PH; Hong HJ
    Exp Mol Med; 2013 Nov; 45(11):e52. PubMed ID: 24176949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.